Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules
MWN-AI** Summary
Avalon GloboCare Corp. (NASDAQ: ALBT), a diversified company focused on precision diagnostic consumer products and generative AI, announced the successful closing of a private placement raising up to $9.75 million. The placement involves the issuance of 6,372,550 shares of common stock (or pre-funded warrants) priced at $0.51 per share, along with Series A-1 and A-2 warrants that enable investors to purchase additional shares at the same price. The Series A-1 warrants will expire five years following stockholder approval, while the Series A-2 warrants will expire in eighteen months.
The private placement garnered approximately $3.25 million in gross proceeds, excluding costs associated with the placement, with potential additional proceeds of around $6.5 million if the warrants are fully exercised. These funds are intended for debt repayment, working capital, and general corporate purposes. The placement was facilitated by H.C. Wainwright & Co. as the exclusive placement agent, with Roth Capital Partners serving as financial advisor.
Avalon’s offering was conducted in compliance with federal securities regulations, specifically under Section 4(a)(2) of the Securities Act of 1933, meaning the securities were only available to accredited investors and not registered for public sale. Consequently, the sale of these securities is subject to SEC regulations.
With a focus on advancing artificial intelligence and innovative medical technologies, Avalon is also known for its KetoAir™ breathalyzer device, FDA-approved as a Class I medical device. The company aims to expand its portfolio in AI-driven solutions and cellular therapy.
Forward-looking statements in the release suggest uncertainty in future outcomes, emphasizing the potential impact of various market conditions and regulatory factors on company performance.
MWN-AI** Analysis
Avalon GloboCare Corp. (NASDAQ: ALBT) has recently concluded a private placement to raise up to $9.75 million, positioning itself strategically within the diagnostics and AI sectors. The company plans to deploy the approximately $3.25 million in initial proceeds toward debt repayment and operational needs, while the potential additional $6.5 million from warrant exercises could significantly boost its financial flexibility.
Investors might find the pricing of $0.51 per share attractive, especially given that it is priced at-the-market. However, prospective shareholders should closely monitor the warrant provisions. The Series A-1 and A-2 warrants, which can be exercised at the same price, present opportunities for existing shareholders to increase their stake or convert their interest into equity. The expiration timelines—five years for Series A-1 and eighteen months for Series A-2—are also noteworthy, affecting investor sentiment and market strategies.
Avalon’s focus on innovative AI-driven solutions, alongside products like the KetoAir™ breathalyzer, indicates a diversified approach to potential revenue streams. The market's reception of this placement may hinge on the effectiveness of these technological advancements and the overall strategic execution of Avalon’s business model.
Given the significant risks associated with the biotechnology and AI sectors, including regulatory hurdles and technological adoption rates, investors should conduct thorough due diligence. Monitoring legislative developments and shifts in industry trends may also provide insight into Avalon’s future performance.
In conclusion, while the immediate capital structure adjustments appear promising, prospective investors should consider the volatility inherent in this sector and Avalon’s capacity to effectively leverage its assets. Strategic accumulation in the stock, particularly if there is a gradual increase in warrant exercises, could yield favorable long-term results.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FREEHOLD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 6,372,550 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share (or pre-funded warrant in lieu thereof) and associated warrants. The warrants have an exercise price of $0.51 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval and the Series A-2 warrants will expire eighteen months from the date of stockholder approval.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Roth Capital Partners acted as financial advisor to the Company.
The aggregate gross proceeds to the Company from the offering were approximately $3.25 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such warrants will become exercisable or will be exercised. The Company intends to use the net proceeds from the offering for the repayment of certain outstanding debt and for working capital and general corporate purposes.
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants sold in the offering, have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the unregistered securities to be issued in the offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a technology-focused company developing and acquiring innovative artificial intelligence platforms. Through its AI-driven subsidiary, Avalon Quantum AI LLC, the Company is advancing next-generation AI systems, including automated video generation, enterprise documentation, and workflow automation solutions. Avalon is also expanding its intellectual property portfolio in cellular therapy and generative AI publishing and software. In addition, Avalon is marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to pursue additional diagnostic applications for the technology.
For more information about Avalon, please visit www.avalon-globocare.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the use of proceeds from the offering, the receipt of stockholder approval for the warrants and the exercise of the warrants prior to their expiration. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
FAQ**
How does Avalon GloboCare Corp. ALBT plan to utilize the $3.25 million raised from its recent private placement to enhance its precision diagnostic consumer product and AI software development?
What measures will Avalon GloboCare Corp. ALBT take to secure stockholder approval for the warrants issued in the recent private placement, and how crucial is this approval for their future financing plans?
Can Avalon GloboCare Corp. ALBT provide more details on the potential additional $6.5 million gross proceeds from the warrants, and what strategies are in place to encourage their exercise by investors?
Given the focus on advanced technologies, how does Avalon GloboCare Corp. ALBT intend to integrate its AI systems with its existing products, like the KetoAir™ breathalyzer, to drive future growth and innovation?
**MWN-AI FAQ is based on asking OpenAI questions about Avalon GloboCare Corp. (NASDAQ: ALBT).
NASDAQ: ALBT
ALBT Trading
-9.23% G/L:
$0.915 Last:
654,625 Volume:
$0.92 Open:
